TITLE

Continuing alendronate for an additional 5 years maintained bone mineral density in postmenopausal women: COMMENTARY

AUTHOR(S)
Baillie, Cory
PUB. DATE
May 2007
SOURCE
ACP Journal Club;May/Jun2007, Vol. 146 Issue 3, p64
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The author comments on a study on the effect of continuing alendronate treatment for 5 years in postmenopausal women with low bone mineral density (BMD). He asserted that the results of the trial may be the best data that clinicians have to investigate to answer the appropriate duration of bisphosphonate therapy for postmenopausal osteoporosis or low BMD. He claimed that researchers appropriately concluded that women at risk for clinical vertebral fracture may benefit from such therapy.
ACCESSION #
25169107

 

Related Articles

  • Psychometric evaluation of the Osteoporosis Patient Treatment Satisfaction Questionnaire (OPSAT-Q), a novel measure to assess satisfaction with bisphosphonate treatment in postmenopausal women. Flood, Emuella M.; Beusterien, Kathleen M.; Green, Hannah; Shikiar, Richard; Baran, Robert W.; Amonkar, Mayur M.; Cella, David // Health & Quality of Life Outcomes;2006, Vol. 4, p42 

    Background: The Osteoporosis Patient Satisfaction Questionnaire (OPSAT-Q) is a new measure of patient satisfaction with bisphosphonate treatment for osteoporosis. The objective of this study was to evaluate the psychometric characteristics of the OPSAT-Q. Methods: The OPSAT-Q contains 16 items...

  • Continuing alendronate for an additional 5 years maintained bone mineral density in postmenopausal women. Black, D. M.; Schwartz, A. V.; Ensrud, K. E. // ACP Journal Club;May/Jun2007, Vol. 146 Issue 3, p64 

    The article presents a study on the effects of the continuing alendronate treatment for 5 years on postmenopausal women with low bone mineral density (BMD). Results revealed that 5 additional years of alendronate maintained total hip BMD compared to a decrease with placebo. It also indicated...

  • Alendronate may help prevent steroid-induced osteoporosis in women.  // Geriatrics;Sep98, Vol. 53 Issue 9, p16 

    Focuses on a study conducted in the United States which reported that bisphosponate alendronate sodium (Fosomax) can prevent and treat postmenopausal osteoporosis and osteoporosis caused by corticosteroid therapy in women. Comments from study co-author, Kenneth Saag; Information on...

  • Bisphosphonates reduce costs--if women take them.  // Contemporary OB/GYN;Nov2006, Vol. 51 Issue 11, p29 

    The article discusses research being done on the influence of bisphosphonates administration on the health care costs associated with osteoporosis care in menopausal women. It references a study by J. Curtis and colleagues, presented at the 17th annual meeting of the North American Menopause...

  • Bisphosphonate drug holidays: Can we recommend currently? Tandon, Vishal R.; Sharma, Sudhaa; Mahajan, Annil // Journal of Mid-life Health;Jul-Sep2014, Vol. 5 Issue 3, p111 

    Bisphosphonates (BP) are the mainstay of treatment for osteoporosis. Subtrochanteric or diaphyseal fractures have been reported with long term use of BP, which raised world-wide debate on two aspects, i.e., for how long the BP is to be given and potential advantages/role of BP drug holidays. BP...

  • Management of osteoporosis in postmenopausal women.  // GP: General Practitioner;12/5/2008, p43 

    The article provides information on key trials of treating osteoporosis in postmenopausal women. One study found that treatment with alendronate has greater reductions in markers of bone turnover and also greater gains in bone mineral density compared with risedronate. On the other hand,...

  • Adherence to Bisphosphonate Therapy and Fracture Rates in Osteoporotic Women: Relationship to Vertebral and Nonvertebral Fractures From 2 US Claims Databases. Siris, Ethel S.; Harris, Steven T.; Rosen, Clifford J.; Barr, Charles E.; Arvesen, James N.; Abboti, Thomas A.; Silverman, Stuart // Mayo Clinic Proceedings;Aug2006, Vol. 81 Issue 8, p1013 

    OBJECTIVE: To characterize the relationships between adherence (compliance and persistence) to bisphosphonate therapy and risk of specific fracture types in postmenopausal women. PATIENTS AND METHODS: Data were collected from 45 employers and 100 health plans in the continental United States...

  • Hepatotoxicity induced by alendronate therapy. Yanık, B.; Turkay, C.; Atalar, H. // Osteoporosis International;Jun2007, Vol. 18 Issue 6, p829 

    Here we describe a 47-year-old postmenopausal woman who had been taking alendronate 70 mg/week for osteoporosis. After two months of alendronate therapy, she developed hepatotoxicity, and no other etiological factors for this besides the alendronate were apparent. After the alendronate therapy...

  • Why Do Women Reject Bisphosphonates for Osteoporosis? A Videographic Study. Scoville, Elizabeth A.; de Leon Lovaton, Paula Ponce; Shah, Nilay D.; Pencille, Laurie J.; Montori, Victor M. // PLoS ONE;2011, Vol. 6 Issue 4, p1 

    Background: Despite access to effective, safe, and affordable treatment for osteoporosis, at-risk women may choose not to start bisphosphonate therapy. Understanding the reasons women give for rejecting a clinician's offer of treatment during consultations and how clinician's react to these...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics